1. Home
  2. HTGC vs ABCL Comparison

HTGC vs ABCL Comparison

Compare HTGC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hercules Capital Inc.

HTGC

Hercules Capital Inc.

HOLD

Current Price

$17.61

Market Cap

2.9B

Sector

Finance

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$11.64

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTGC
ABCL
Founded
2003
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.5B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
HTGC
ABCL
Price
$17.61
$11.64
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$18.86
$8.40
AVG Volume (30 Days)
1.8M
9.0M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
12.13%
N/A
EPS Growth
14.91
10.91
EPS
0.90
N/A
Revenue
N/A
$75,128,000.00
Revenue This Year
$11.18
N/A
Revenue Next Year
$5.24
$21.85
P/E Ratio
$19.47
N/A
Revenue Growth
N/A
160.56
52 Week Low
$13.70
$2.75
52 Week High
$19.62
$12.58

Technical Indicators

Market Signals
Indicator
HTGC
ABCL
Relative Strength Index (RSI) 65.28 71.38
Support Level $16.97 $3.38
Resistance Level $19.05 N/A
Average True Range (ATR) 0.23 0.81
MACD 0.05 0.13
Stochastic Oscillator 85.37 93.58

Price Performance

Historical Comparison
HTGC
ABCL

About HTGC Hercules Capital Inc.

Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: